Subtype
Female Reproductive System Neoplasm
CI-CAN-00000885Explore in graph →
Non-malignant1,630 active trials11 approved drugs139 evidence items
Loading cancer entity…
Subtype
CI-CAN-00000885Explore in graph →
Clinical trials
7,171 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05799274 | Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors(RAD301) | active not recruiting | Phase 1 | 9 | Radiopharm Theranostics, LtdINDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05858736 | Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors(PRESERVE-009) | completed | Phase 1 | 18 | OncoC4, Inc.INDUSTRY | 1 | Sep 14, 2026 |
| clinicaltrials |
| NCT06263283 | Impact of an Educational Physiotherapy-Yoga Intervention on Perceived Stress in Women Treated With Brachytherapy for Cervical Cancer(KYOCOL) | completed | N/A | 98 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06303505 | FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC(NAPISTAR1-01) | recruiting | Phase 1 / Phase 2 | 250 | Tubulis GmbHINDUSTRY | 8 | Sep 14, 2026 | clinicaltrials |
| NCT06359431 | A Novel Smart Speculum Versus a Standard Speculum for Easy Visualisation of the Cervix and Performing Remote Cervical Cancer Screening | completed | N/A | 81 | GICMEDOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06433219 | Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) | completed | Phase 2 | 63 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 13 | Sep 14, 2026 | clinicaltrials |
| NCT06674811 | Biomarkers of Resiliency In Childhood Cancer Surgery(BRICCS) | recruiting | — | 40 | Mayo ClinicOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06787612 | Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer | recruiting | Phase 2 | 297 | Regeneron PharmaceuticalsINDUSTRY | 5 | Sep 14, 2026 | clinicaltrials |
| NCT07098182 | Contribution of Preserving the Superior Left Colic Artery to the Vascularization of the Descending Colon Prior to Colorectal Anastomosis During Left-Sided or Rectal Resections for Colorectal or Ovarian Cancer. (Revascularisation Colique) | recruiting | N/A | 50 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07539844 | Study to Assess Prevalence of the Folate Receptor Alpha (FRa) in Adult Female Participants With Ovarian Cancer in Intercontinental (InterCon) Countries(ConFeR) | recruiting | — | 1,000 | AbbVieINDUSTRY | 5 | Sep 14, 2026 | clinicaltrials |
| NCT07772869 | Uterine Lavage to Detect Ovarian Cancer Risk | recruiting | N/A | 75 | University of WashingtonOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04633239 | Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer | recruiting | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Sep 11, 2026 | clinicaltrials |
| NCT04905082 | HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics | active not recruiting | N/A | 465 | City of Hope Medical CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05081609 | A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies(IL Believe) | active not recruiting | Phase 1 / Phase 2 | 320 | Ascendis Pharma Oncology Division A/SINDUSTRY | 10 | Sep 11, 2026 | clinicaltrials |
| NCT05123482 | A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies | recruiting | Phase 1 / Phase 2 | 460 | AstraZenecaINDUSTRY | 15 | Sep 11, 2026 | clinicaltrials |
| NCT05979493 | QL Block in Laparoscopic Myomectomy | recruiting | Phase 4 | 80 | Joseph Findley MDOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06840002 | A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer | recruiting | Phase 1 / Phase 2 | 150 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06964009 | DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer | recruiting | Phase 1 | 30 | Elizabeth Stover, MD, PhDOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07065552 | Tirzepatide in Obesity-Driven Endometrial Cancer | recruiting | Early Phase 1 | 20 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07181720 | CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors | suspended | Phase 1 | 90 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07546578 | Setting Up ctDNA Analysis on Archived Plasma Samples(DARE-part1) | recruiting | — | 50 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07743164 | A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05) | not yet recruiting | Phase 3 | 646 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 11, 2026 | clinicaltrials |
| NCT07764744 | Ovarian Cancer Liquid Biopsy for Early Assessment & Detection in Individuals With BRCA1/2 Pathogenic Variants(OC-LEAD) | not yet recruiting | N/A | 70 | Weill Medical College of Cornell UniversityOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07814872 | A Preregistered Multi-Cohort Evaluation of the FATHOM AI System for Molecular Testing Prioritization to Support Clinical Trial Enrollment(FATHOM) | not yet recruiting | — | 30,000 | Harvard Medical School (HMS and HSDM)OTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07815704 | Targeting Immune Modulation in High Grade Serous Carcinoma: Combined Effects of Chemotherapy and Atorvastatin | not yet recruiting | Phase 2 | 40 | University of Colorado, DenverOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07815873 | Gut Microbiome in Patients With Lung and Melanoma Cancer and Intestinal Microbiota in Gynecologic Cancers(CERBERO) | not yet recruiting | N/A | 360 | European Institute of OncologyOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07815951 | Safety and Diagnostic Performance of 111In-TJD-31 SPECT Imaging in Patients With Solid Tumors | not yet recruiting | Phase 1 | 8 | Yong HeOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07816263 | Guaraná Supplementation for Cancer-Related Fatigue(GUARANA-CRF) | recruiting | — | 60 | Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento AnguloOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT02101775 | Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | active not recruiting | Phase 2 | 124 | National Cancer Institute (NCI)NIH | 3 | Sep 10, 2026 | clinicaltrials |
| NCT02397083 | Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer(LEVER) | active not recruiting | Phase 2 | 102 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT04683653 | Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer | suspended | Phase 1 / Phase 2 | 100 | University of ChicagoOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT04865887 | Pembrolizumab and Lenvatinib in Advanced Cervical Cancer | recruiting | Phase 2 | 35 | Georgetown UniversityOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT04931342 | A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors(BOUQUET) | active not recruiting | Phase 2 | 176 | Hoffmann-La RocheINDUSTRY | 13 | Sep 10, 2026 | clinicaltrials |
| NCT05316935 | GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients | recruiting | Phase 2 / Phase 3 | 80 | Xiaojun ChenOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06293898 | Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors | recruiting | Phase 1 | 280 | SystImmune Inc.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06379113 | GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients | recruiting | Phase 2 / Phase 3 | 29 | Xiaojun ChenOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06646627 | Clinical Trial of Autologous B7-H3 CAR T Cells in Reoccurent Platinum-resistant Ovarian Tumors | recruiting | Phase 1 | 48 | Stanford UniversityOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07090109 | PITCH - Impacting Hereditary Cancer Testing | not yet recruiting | N/A | 200 | Rachel MillerOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07502157 | Massage, Oncology, Pain, Anxiety, Feasibility(IMPACT) | recruiting | N/A | 24 | Jill ColeOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07811232 | A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast Cancers | not yet recruiting | Phase 1 / Phase 2 | 138 | Advenchen Pharmaceuticals, LLC.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07811271 | Efficacy and Safety of BG-C9074 With Bevacizumab Compared With Bevacizumab in Adults With Ovarian, Fallopian Tube, or Primary Peritoneal Cancers | not yet recruiting | Phase 3 | 600 | BeOne MedicinesINDUSTRY | 0 | Sep 10, 2026 | clinicaltrials |
| NCT07811297 | A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers | not yet recruiting | Phase 1 / Phase 2 | 138 | Advenchen Pharmaceuticals, LLC.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07811375 | Perioperative Adebrelimab for Locally Advanced Cervical Cancer(ADE-LACC) | not yet recruiting | Phase 2 | 35 | Anhui Provincial HospitalOTHER_GOV | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07812636 | Tirzepatide and Levonorgestrel IUD Therapy for EIN and Early-Stage Endometrial Cancer(TIDE) | not yet recruiting | Early Phase 1 | 15 | Milton S. Hershey Medical CenterOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT00977574 | Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer | active not recruiting | Phase 2 | 349 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT02595892 | Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | active not recruiting | Phase 2 | 70 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT03367741 | Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer | active not recruiting | Phase 2 | 82 | National Cancer Institute (NCI)NIH | 2 | Sep 9, 2026 | clinicaltrials |
| NCT03651206 | Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib(ROCSAN) | recruiting | Phase 2 / Phase 3 | 138 | ARCAGY/ GINECO GROUPOTHER | 3 | Sep 9, 2026 | clinicaltrials |
| NCT06834672 | Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | active not recruiting | Phase 3 | 450 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07166094 | Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer(RAINFOL-03) | recruiting | Phase 3 | 660 | GenmabINDUSTRY | 19 | Sep 9, 2026 | clinicaltrials |
Data updated 17 days agoSource updated Sep 14, 2026source: clinicaltrials